Gene · 6196
RPS6KA2: ribosomal protein S6 kinase A2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPS6KA2: ribosomal protein S6 kinase A2. Genes, record 6196. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6196
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q15349 | Ribosomal protein S6 kinase alpha-2 | 733 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents49
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12569486 B2 | 2026-03-10 | 2 | Q15349 | Espacenet |
| JP 2026505638 A | 2026-02-16 | 10 | Q15349 | Espacenet |
| EP 4665851 A2 | 2025-12-24 | 10 | Q15349 | Espacenet |
| JP 2025041721 A | 2025-03-26 | 1 | Q15349 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8240 | Q15349 | Espacenet |
| US 11944625 B2 | 2024-04-02 | 2 | Q15349 | Espacenet |
| US 11938198 B2 | 2024-03-26 | 1 | Q15349 | Espacenet |
| US 11931402 B2 | 2024-03-19 | 1 | Q15349 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74424 | Q15349 | Espacenet |
| JP 2022532763 A | 2022-07-19 | 12 | Q15349 | Espacenet |
1 to 10 of 49
See all 49 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| TAS0612 | CHEMBL4650277 | p90RSK inhibitor | INHIBITOR |
Source ChEMBL
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,170
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPS6KA2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 30 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 17 | 2025 |
| R01CA046595 | Mitogenic and Oncogenic Regulation of ERK/RSK Signaling | 12 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 10 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 8 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 7 | 2025 |
| P30CA056036 | Translational Research in Cancer | 6 | 2025 |
| T32CA071341 | Cancer Cell Biology Training Program | 6 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 5 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
1 to 10 of 2,170Source NIH's project files
See all 2,170 nih grantsPapers2,567
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MAPK signaling links BRD2 chromatin occupancy to PI3K/AKT inhibitor sensitivity. | bioRxiv | 2026 | 42818240 | PubTator, text mining | PubMed |
| A multi-omics Mendelian randomization study identifies putatively causal genes and pathways for Alzheimer's disease associated with reactive astrocytes. | J Alzheimers Dis | 2026 | 42775789 | PubTator, text mining | PubMed |
| Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma. | Int J Mol Sci | 2026 | 42737619 | PubTator, text mining | PubMed |
| PDK1 signaling in cancer: Current status and future perspectives. | Int J Biol Macromol | 2026 | 42716156 | PubTator, text mining | PubMed |
| Investigation of psychosocial stress and DNA methylation in genes related to immune response, metabolism, and calcium signaling among African American and White middle-aged adults. | Environ Epigenet | 2026 | 42698993 | PubTator, text mining | PubMed |
| Genomic insights into stroke recovery: cross-phenotype associations. | Brain Commun | 2026 | 42695012 | PubTator, text mining | PubMed |
| Placental Epigenetic Alterations and IL-10 Dysregulation Drive Early Persistent Food Allergy. | Allergy | 2026 | 42618975 | PubTator, text mining | PubMed |
| Construction and validation of a nomogram for the diagnosis of postmenopausal osteoporosis. | Mol Med Rep | 2026 | 42596822 | PubTator, text mining | PubMed |
| Integrating dynamic modeling of signaling pathways with subject-specific transcriptomic data to assess breast cancer risk. | PLoS One | 2026 | 42594127 | PubTator, text mining | PubMed |
| EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy delivery. | J Cell Biol | 2026 | 42578958 | PubTator, text mining | PubMed |
1 to 10 of 2,567
See all 2,567 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6196
GET https://conductscience.org/api/genes/v1/6196/patents?page=2